ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,505.00
-0.71%
US Tech 100
19,000.00
-0.94%
Dow Jones
40,287.53
-0.93%
Brent Oil
82.295
0.02%
Bitcoin
67,952.24
-0.30%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Mustang Bio Inc (MBIO)

  7. Mustang Bio Inc (MBIO) News

MBIO

Mustang Bio (MBIO)

Mustang Bio Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MBIO
DateTimeSourceHeadlineSymbolCompany
07/19/20245:26PMEdgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:MBIOMustang Bio Inc
07/10/20244:41PMEdgar (US Regulatory)Form DEF 14C - Other definitive information statementsNASDAQ:MBIOMustang Bio Inc
06/21/20244:01PMGlobeNewswire Inc.Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:MBIOMustang Bio Inc
06/20/20248:00AMGlobeNewswire Inc.Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:MBIOMustang Bio Inc
06/20/20248:00AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MBIOMustang Bio Inc
06/17/20248:30AMGlobeNewswire Inc.Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T TherapyNASDAQ:MBIOMustang Bio Inc
06/13/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MBIOMustang Bio Inc
06/06/20245:00PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
06/04/20248:35PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MBIOMustang Bio Inc
06/04/20248:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MBIOMustang Bio Inc
05/31/20245:09PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:MBIOMustang Bio Inc
05/21/20244:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
05/13/20246:01AMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:MBIOMustang Bio Inc
05/02/20244:01PMGlobeNewswire Inc.Mustang Bio Announces Closing of $4 Million Public OfferingNASDAQ:MBIOMustang Bio Inc
04/29/20248:00PMGlobeNewswire Inc.Mustang Bio Announces Pricing of $4 Million Public OfferingNASDAQ:MBIOMustang Bio Inc
03/28/20249:00AMGlobeNewswire Inc.Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune DiseasesNASDAQ:MBIOMustang Bio Inc
03/11/20244:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
03/11/20244:05PMGlobeNewswire Inc.Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate HighlightsNASDAQ:MBIOMustang Bio Inc
03/11/20244:02PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:MBIOMustang Bio Inc
03/07/20247:30AMGlobeNewswire Inc.Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade GliomaNASDAQ:MBIOMustang Bio Inc
02/14/20244:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
01/25/20244:07PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
01/11/20248:30AMGlobeNewswire Inc.Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology ConferenceNASDAQ:MBIOMustang Bio Inc
01/04/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
12/19/20234:06PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MBIOMustang Bio Inc
12/11/20239:52PMEdgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:MBIOMustang Bio Inc
12/11/20238:37AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
12/11/20238:30AMGlobeNewswire Inc.Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual MeetingNASDAQ:MBIOMustang Bio Inc
11/14/20234:44PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
11/14/20234:05PMGlobeNewswire Inc.Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:MBIOMustang Bio Inc
 Showing the most relevant articles for your search:NASDAQ:MBIO

Your Recent History

USOTC
BIEL
Bioelectronics (PK)
USOTC
SPZI
Spooz (PK)
USOTC
HIRU
Hiru (PK)
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
RONN
Ronn Motor (PK)
COIN
BTCUSD
Bitcoin
NASDAQ
AVXL
Anavex Life Sciences
NASDAQ
COOP
Mr Cooper
USOTC
VPLM
Voip Pal Com (QB)
USOTC
KEGS
1812 Brewing (PK)
USOTC
DBMM
Digital Brand Media and ... (PK)
NASDAQ
LWLG
Lightwave Logic
USOTC
NWBO
Northwest Biotherapeutics (QB)
NASDAQ
AMRN
Amarin
USOTC
IGPK
Intergrated Cannabis Sol... (PK)
USOTC
NSAV
Net Savings Link (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved